Literature DB >> 19389443

A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection.

Megan M Crumpler1, K Yeon Choi, Michael A McVoy, Mark R Schleiss.   

Abstract

Live attenuated vaccines for prevention of congenital cytomegalovirus infections encode numerous immune evasion genes. Their removal could potentially improve vaccine safety and efficacy. To test this hypothesis, three genes encoding MHC class I homologs (presumed NK evasins) were deleted from the guinea pig cytomegalovirus genome and the resulting virus, 3DX, was evaluated as a live attenuated vaccine in the guinea pig congenital infection model. 3DX was attenuated in vivo but not in vitro. Vaccination with 3DX produced elevated cytokine levels and higher antibody titers than wild type (WT) virus while avidity and neutralizing titers were similar. Protection, assessed by maternal viral loads and pup mortality following pathogenic viral challenge during pregnancy, was comparable between 3DX and WT and significant compared to naïve animals. These results suggest that the safety and perhaps efficacy of live attenuated human cytomegalovirus vaccines could be enhanced by deletion of viral immunomodulatory genes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389443      PMCID: PMC3539795          DOI: 10.1016/j.vaccine.2009.04.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  62 in total

1.  Congenital cytomegalovirus: immunological alterations.

Authors:  R Cauda; E F Prasthofer; C E Grossi; R J Whitley; R F Pass
Journal:  J Med Virol       Date:  1987-09       Impact factor: 2.327

2.  The placenta as a site of cytomegalovirus infection in guinea pigs.

Authors:  B P Griffith; S R McCormick; C K Fong; J T Lavallee; H L Lucia; E Goff
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.

Authors:  S A Plotkin; M L Smiley; H M Friedman; S E Starr; G R Fleisher; C Wlodaver; D C Dafoe; A D Friedman; R A Grossman; C F Barker
Journal:  Lancet       Date:  1984-03-10       Impact factor: 79.321

4.  Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.

Authors:  H H Balfour; G W Sachs; P Welo; R C Gehrz; R L Simmons; J S Najarian
Journal:  Birth Defects Orig Artic Ser       Date:  1984

5.  Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome.

Authors:  S Stagno; R F Pass; G Cloud; W J Britt; R E Henderson; P D Walton; D A Veren; F Page; C A Alford
Journal:  JAMA       Date:  1986-10-10       Impact factor: 56.272

6.  Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.

Authors:  K L Brayman; D C Dafoe; W R Smythe; C F Barker; L J Perloff; A Naji; I J Fox; R A Grossman; D K Jorkasky; S E Starr
Journal:  Arch Surg       Date:  1988-12

7.  Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.

Authors:  S A Plotkin; S E Starr; H M Friedman; K Brayman; S Harris; S Jackson; N B Tustin; R Grossman; D Dafoe; C Barker
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

8.  Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer.

Authors:  M A McVoy; S P Adler
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  The outcome of congenital cytomegalovirus infection in relation to maternal antibody status.

Authors:  K B Fowler; S Stagno; R F Pass; W J Britt; T J Boll; C A Alford
Journal:  N Engl J Med       Date:  1992-03-05       Impact factor: 91.245

10.  Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.

Authors:  J F Bukowski; B A Woda; R M Welsh
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

View more
  25 in total

1.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Authors:  Mark R Schleiss
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

4.  Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Authors:  Mark R Schleiss; Craig J Bierle; Elizabeth C Swanson; Michael A McVoy; Jian Ben Wang; Zainab Al-Mahdi; Adam P Geballe
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 5.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

6.  Inclusion of the Viral Pentamer Complex in a Vaccine Design Greatly Improves Protection against Congenital Cytomegalovirus in the Guinea Pig Model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 7.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

8.  Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.

Authors:  Michael A McVoy; Jian Ben Wang; Dirk P Dittmer; Craig J Bierle; Elizabeth C Swanson; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jason C Zabeli; Mark R Schleiss
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

9.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

10.  An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Authors:  Mark R Schleiss; Ryan Buus; K Yeon Choi; Alistair McGregor
Journal:  Future Virol       Date:  2013-12-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.